Implementation of Pharmacogenomics and Artificial Intelligence Tools for Chronic Disease Management in Primary Care Setting
- P. SilvaD. Jacobs Kenneth S. Ramos
- 21 May 2021
Medicine, Computer Science
Chronic disease management often requires use of multiple drug regimens that lead to polypharmacy challenges and suboptimal utilization of healthcare services. While the rising costs and healthcare…
An Idealized Clinicogenomic Registry to Engage Underrepresented Populations Using Innovative Technology
- P. SilvaD. Dahlke Kenneth Ramos
- 29 April 2022
Medicine
The parameters of an idealized clinical genomic registry are presented and distributed ledger technologies (specifically blockchain) offer a significant element of trust that can be used to engage URM populations more substantively in clinical research.
Case Report: Life-Threatening Fluoxetine-Linked Postoperative Bleeding Informed by Pharmacogenetic Evaluation
- S. RogersP. Silva Kenneth S. Ramos
- 28 February 2024
Medicine
The case of a 52-year-old patient who developed severe postsurgical bleeding requiring blood transfusion following panniculectomy is presented.
Academic medical centers as innovation ecosystems to address population –omics challenges in precision medicine
- P. SilvaValerie M. SchaibleyK. Ramos
- 15 February 2018
Medicine, Engineering
A rebalancing of proprietary strategies and open innovation strategies is warranted to enable institutional precision medicine asset portfolios.
MULTICRITERIA DECISION SUPPORT MODEL FOR DECOMMISSIONING PROJECTS IN THE OIL AND GAS SECTOR
- M. P. CardosoP. Silva
- 10 July 2025
Engineering, Environmental Science
Brazilian offshore production fields are maturing, requiring decommissioning structures and equipment, such as platforms and subsea pipelines, therefore, presenting challenges to its oil and gas…
External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations
- P. SilvaN. Janjan Matthew Lee Smith
- 6 July 2023
Medicine, Environmental Science
Examining covariates of the clinical outcomes in ECAs that are being measured in the interventional arm can be particularly useful in phase 2 trials to better understand social and genetic determinants of clinical outcomes that might inform pivotal trial design.
Precision medicine at the academic-industry interface
Academic medical centers are at the forefront of developing infrastructure to interface with these challenges, and are thus, a focal point of industry engagement, in the development and validation of precision medicine technology, products, and decision rules.